Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia

British Journal of Haematology

Volumn 92, Issue 3, 1996, Pages 620-626

  Brune, Mats ^a   Hellstrand, Kristoffer ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myelogenous leukaemia; Histamine; IL 2; Immunotherapy; NK cells

Indexed keywords

CYTARABINE; HISTAMINE; INTERLEUKIN 2; RANITIDINE; RECOMBINANT INTERLEUKIN 2; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HEADACHE; HUMAN; HYPOTENSION; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029980720     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.00389.x     Document Type: Article

References (23)

1. Archimbaud, E., Bailly, M. & Doré, J.F. (1991) Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. British Journal of Haematology, 77, 328-334.
2. Asea, A. (1995) Role of histamine in the regulation of natural killer cells. Thesis. University of Göteborg.
3. Asea, A., Hermodsson, S. & Hellstrand, K. (1995) Histaminergic regulation of natural killer cell-mediated clearance of tumor cells in vivo. Scandinavian Journal of Immunology in press.
4. Caron, P.C. & Scheinberg, D.A. (1994) Immunotherapy for acute leukemias. Current Opinion in Oncology, 16, 14-22.
5. Foa, R., Meloni, G., Tosti, S., Novarino, A., Fenu, S., Gavosto, F. & Mandelli, F. (1991) Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. British Journal of Haematology, 77, 491-496.
6. Hamon, M.D., Prentice, H.G., Gottlieb, D.J., Macdonald, I.D., Cunningham, J.M., Smith, O.P., Gilmore, M., Gandhi, L. & Collis, C. (1993) Immunotherapy with IL-2 after AMBT in AML. Bone Marrow Transplantation, 11, 399-405.
7. Hellstrand, K., Asea, A., Dahlgren, C. & Hermodsson, S. (1994a) Histaminergic regulation of natural killer cells: role of monocyte-derived, reactive oxygen metabolites. Journal of Immunology, 153, 4940-4947.
8. Hellstrand, K., Asea, A. & Hermodsson, S. (1990) Role of histamine in natural killer cell-mediated resistance against tumor cells. Journal of Immunology, 145, 4365-4370.
9. Hellstrand, K. & Hermodsson, S. (1990) Synergistic NK cell activation by histamine and IL-2. International Archives of Allergy and Applied Immunology, 92, 379-388.
10. 2-receptors. Scandinavian Journal of Immunology, 34, 741-750.
11. Hellstrand, K., Naredi, P., Lindner, P., Lundholm, K., Hermodsson, S., Rudenstam, C.-M., Azstély. M. & Hafström. L.-O. (1994b) Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunology and Immunotherapy, 39, 416-419.
12. Kay, A.W. (1953) Effect of large doses of histamine on gastric-secretion of HCl: an augmented histamine test. British Medical Journal, ii, 77-80.
13. Keating, M.J., Kantarjian, H., Smith, T.L., Eskey, E., Walters, R., Andersson, B., Beran, M. & Freireich, E.J. (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. Journal of Clinical Oncology, 7, 1071.
14. Lauria, F., Raspadori, D., Rondelli, D., Ventura, M.A. & Foa, R. (1994) In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia, 8, 724-728.
15. Lotzovà, E., Savary, C.A. & Herberman, R.B. (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. Journal of Immunology, 138, 2718-2727.
16. MacDonald, D., Jiang, Y.Z. & Gordon, A.A. (1990) Recombinant IL 2 for acute myeloid leukemia in lirst complete remission: a pilot study. Leukemia Research, 14, 967-973.
17. Oshimi, K., Oshimi, Y., Akutsi, M., Saito, H., Okada, M. & Mizoguchi, H. (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood, 68, 938-948.
18. Prentice, H.G., Macdonald, I.D. & Hamon, M.D. (1993) The role of immunotherapy in the treatment of acute myeloblastic leukemia: from allogeneic bone marrow transplantation to the application of IL 2. Cancer Treatment Research, 64, 121-134.
19. Shepherd, J.D., Jacky, E., Grathwohl, A., Helbig, W., Maranchini, D., Zittoun, R., Newland, A., Prentice, A., Selleslag, D., Fey, M., Cavalli, F., Hess, U., Bell, A., Prentice, H.G., Gerhartz, H.H., Mertelsman, R., Fenaux, P., Bosly, A., Ferrant, A., Gluck, S., Michal, S. & Osterwalder, B. (1994) Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukaemia in partial or complete second remission and partial relapse. British Journal of Haematology, 87, (Suppl.), 205.
20. Smith, K.A. (1993) Lowest dose interleukin-2 immunotherapy. Blood, 81, 1414-1423.
21. Trinchieri, G. (1989) Biology of natural killer cells. Advances in Immunology, 47, 187-376.
22. Vourka-Karussis, Levi-Schaffer, F. & Slavin, S. (1995) Investigation on the role of inflammatory and anti-inflammatory agents on the treatment of murine B cell leukemia by recombinant IL-2. Experimental Haematology, 21, 93-100.
23. Yasaka, T., Mantich, N.M., Boxer, L.A. & Baehner, B.L. (1981) Functions of human monocyte and lymphocyte subsets obtained by countercurrent centrifugal elutriation: differing functional capacities of human numocyte subsets. Jounal of Immunology, 127, 1515-1518.